ArticleCell communication and signaling : CCS2026
Kaempferol-modified mesenchymal stem cell extracellular vesicle-mimetics promote photoaging repair by suppressing ADAM10.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic ultraviolet B (UVB) exposure accelerates skin photoaging by inducing excessive reactive oxygen species (ROS), inflammation, and extensive extracellular matrix (ECM) degradation. Increasing evidence indicates that extracellular vehicles (EVs) derived from mesenchymal stem cells (MSCs) hold promise for mitigating skin photoaging; however, the low yield of naturally secreted EVs poses a significant challenge to their clinical scalability. To overcome this barrier, we generated MSC-derived extracellular vesicle mimetics (MSC-EVMs), which preserved the bioactivity of EVs while enabling high-efficiency production. We further engineered a hybrid nanoplatform-MSC-EVM@Kae-by loading kaempferol (Kae), a natural inhibitor of the ECM-degrading protease ADAM10 with strong antioxidative and anti-inflammatory properties.MSC-EVM@Kae markedly reduced ROS accumulation, DNA damage, and cellular senescence in UVB-irradiated fibroblasts and keratinocytes, while restoring MMP/TIMP homeostasis through ADAM10 suppression. In a UVB-induced photoaging mouse model, microneedle-assisted transdermal delivery of MSC-EVM@Kae significantly improved wrinkle severity, enhanced collagen deposition, and reinforced epidermal barrier integrity.Collectively, our findings demonstrate that kaempferol-loaded MSC-EVM integrate the inherent regenerative potential of MSC-derived vesicles with the pharmacological inhibition of ADAM10, offering a scalable and bioengineered strategy for combating UVB-induced photoaging. This hybrid system provides a promising foundation for next-generation, cell-free therapeutics targeting skin aging and oxidative stress-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.